INVO Fertility Sees 33% Share Jump After Reverse Split, Files for IPO
By ATTN Desk · Editorial oversight: Sean Han
Introduction
INVO Fertility Inc (NASDAQ: IVF) is a healthcare services company specializing in assisted reproductive technology. Founded in 2009, the company develops and operates fertility clinics and distributes its proprietary INVOcell® medical device, which enables intravaginal culture (IVC) and allows fertilization and early embryo development to occur inside the patient’s body.
Corporate Structure and Experience
INVO Fertility employs between 11 and 50 professionals with expertise in medical device engineering, reproductive health, and clinical support. The company operates two dedicated INVO Centers and one in vitro fertilization (IVF) clinic in the United States. Through partnerships, it also provides training and laboratory resources to third-party fertility clinics using the INVOcell system.
Fertility Technology by Ubaid E. Alyafizi
Developments and News
On July 21, 2025, INVO Fertility completed a 1-for-3 reverse stock split to comply with Nasdaq’s $1.00 minimum bid price requirement. Every three shares outstanding were consolidated into one share, reducing the total issued shares to approximately 928,272.
On August 12–18, 2025, the company reported second-quarter 2025 results showing a net loss of US$3.21 million and a loss per share of US$8.07, remaining consistent with results from 2Q 2024. Management forecasts average annual revenue growth of 9.7% over the next three years, compared with an 8.2% forecast for the Medical Equipment industry.
On October 14, 2025, INVO Fertility filed a Form S-1 with the SEC, registering its securities for a planned public offering, categorizing the company as an Emerging Growth Company under the JOBS Act.
Financial and Strategic Analysis
As of October 22, 2025, key metrics include:
| Metric | Value |
|---|---|
| Share Price | US$ 0.72 (up 33.33%) |
| Volume | 1,290,997 |
| Market Capitalization | US$ 3.65 million |
| Trailing-12-Month Revenue | US$ 6.62 million |
| Net Income (TTM) | –US$ 10.21 million |
| Price/Sales (TTM) | 0.01 |
| Total Cash (mrq) | US$ 0.55 million |
| Total Debt/Equity (mrq) | 270.77% |
The reverse stock split aimed to maintain compliance with Nasdaq's listing requirements, although success in compliance cannot be assured. High leverage and a history of net losses highlight the need for revenue expansion and cost control. The company's strategy focuses on broadening access to IVC through its clinic operations and third-party distribution.
Market Position and Industry Context
INVO Fertility holds the only FDA-cleared and CE-marked device for intravaginal culture. By enabling fertilization within the patient’s body, INVOcell aims to reduce treatment costs in comparison to traditional IVF and serves as an alternative to intrauterine insemination (IUI). The company’s two INVO Centers and affiliated clinics position it in a niche within the US fertility market, which is projected to grow in alignment with broader medical equipment industry forecasts.
TL;DR
On July 21, 2025, INVO Fertility implemented a 1-for-3 reverse stock split. Second-quarter 2025 results indicated a US$3.21 million net loss, with management projecting 9.7% annual revenue growth over three years. The share price increased by 33.33% to US$ 0.72 on October 22, 2025, as the company pursues a public offering following its October 14 S-1 filing. The future outlook focuses on achieving sustained revenue growth through INVOcell adoption and clinic expansion.